Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986258

Next Previous
Drug Profile

BMS 986258

Alternative Names: BMS-986258; ONO 7807

Latest Information Update: 29 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; Five Prime Therapeutics
  • Developer Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action HAVCR2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 20 Jan 2025 Bristol-Myers Squibb terminates a phase-II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US, Australia, Canada and Japan (Parenteral) as business objectives have changed (NCT03446040)
  • 06 Jan 2023 Phase II developement in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) still ongoing in Japan (Parenteral) (NCT03446040)
  • 16 Apr 2021 Five Prime Therapeutics has been acquired by Amgen

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top